Evidence map›Paper›PMID 34249433›Full record

ArticleAmerican journal of cancer research2021

A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy.

Nandini Dey, Jennifer Aske, Xiaoqian Lin, Yuliang Sun, Brian Leyland-Jones, Lori Friedman, Pradip De

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. AnFrontiers in bioengineering and biotechnology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Nandini DeyTranslational Oncology Laboratory, Avera Cancer Institute Sioux Falls, SD, USA.
Jennifer AskeTranslational Oncology Laboratory, Avera Cancer Institute Sioux Falls, SD, USA.
Xiaoqian LinTranslational Oncology Laboratory, Avera Cancer Institute Sioux Falls, SD, USA.
Yuliang SunCancer Genomics, Avera Cancer Institute Sioux Falls, SD, USA.
Brian Leyland-JonesNational Foundation for Cancer Research Rockville, MD, USA.
Lori FriedmanGenentech Inc South San Francisco, CA, USA.
Pradip DeTranslational Oncology Laboratory, Avera Cancer Institute Sioux Falls, SD, USA.
Avera Health · USUniversity of Sioux Falls · USAcentech (United States) · USNational Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HER2 signaling network and its complex relationship with the PI3K-AKT-mTOR pathway explain the acquired resistance to anti-HER2 therapy observed in clinics. Such complexity has been clinically evident from the limited efficacy of data in the BOLERO-1 and BOLERO-3 trials, which tested combinations of trastuzumab (T), everolimus, and chemotherapy in women with HER2+ advanced BC. In the following MARIANNE trial also, a combination of T-DM1 plus pertuzumab delivered a non-inferior but yet not superior PFS compared to trastuzumab plus a taxane. Algorithmic inhibition of PI3K/mTOR along with T or T-DM1 is, therefore, an attractive drug combination, and we tested the combination(s) in HER2+ BC, especially in T-resistant and

Indexed as

angiogenesisapoptosisBreast cancerHER2+PIK3CA mutationtrastuzumab-resistanttrastuzumab-sensitive

Identifiers

PMID34249433
PMCPMC8263639
OpenAlexW3177808128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.